Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan.
about
Current and future pharmacological therapies for NAFLD/NASH.Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography.Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitusA Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care
P2860
Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Concomitant screening for live ...... etic patients using Fibroscan.
@en
Concomitant screening for live ...... etic patients using Fibroscan.
@nl
type
label
Concomitant screening for live ...... etic patients using Fibroscan.
@en
Concomitant screening for live ...... etic patients using Fibroscan.
@nl
prefLabel
Concomitant screening for live ...... etic patients using Fibroscan.
@en
Concomitant screening for live ...... etic patients using Fibroscan.
@nl
P2093
P2860
P356
P1433
P1476
Concomitant screening for live ...... etic patients using Fibroscan.
@en
P2093
Françoise Roudot-Thoraval
Ghassan Elourimi
Gisele NKontchou
Hervé Le Clesiau
Jean-Luc Costes
Michel Beaugrand
Narcisse Kouacou
P2860
P304
P356
10.1111/LIV.13481
P577
2017-05-27T00:00:00Z